Progen Pharmaceuticals Limited - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 67

Progen Pharmaceuticals Limited – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Progen Pharmaceuticals Limited - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Progen Pharmaceuticals Limited - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Progen Pharmaceuticals Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Progen Pharmaceuticals Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Progen Pharmaceuticals Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Progen Pharmaceuticals Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Progen Pharmaceuticals Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Progen Pharmaceuticals Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Progen Pharmaceuticals Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Progen Pharmaceuticals Limited and identify potential opportunities in those areas.

List of Tables
List of Figures
Progen Pharmaceuticals Limited Snapshot
Progen Pharmaceuticals Limited Overview
Key Information
Key Facts
Progen Pharmaceuticals Limited – Research and Development Overview
Key Therapeutic Areas
Progen Pharmaceuticals Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Progen Pharmaceuticals Limited – Pipeline Products Glance
Progen Pharmaceuticals Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Progen Pharmaceuticals Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Progen Pharmaceuticals Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Progen Pharmaceuticals Limited – Drug Profiles
Muparfostat
Product Description
Mechanism of Action
R&D Progress
Muparfostat
Product Description
Mechanism of Action
R&D Progress
Muparfostat + docetaxel
Product Description
Mechanism of Action
R&D Progress
PI-88 + Dacarbazine
Product Description
Mechanism of Action
R&D Progress
PG-11047 + 5-Flurouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
PG-11047 + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
PG-11047 + Cisplatin
Product Description
Mechanism of Action
R&D Progress
PG-11047 + Docetaxel
Product Description
Mechanism of Action
R&D Progress
PG-11047 + Erlotinib
Product Description
Mechanism of Action
R&D Progress
PG-11047 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
PG-11047 + Sunitinib
Product Description
Mechanism of Action
R&D Progress
PG11047
Product Description
Mechanism of Action
R&D Progress
Epigenetics
Product Description
Mechanism of Action
R&D Progress
PG11000 Series
Product Description
Mechanism of Action
R&D Progress
PG11047
Product Description
Mechanism of Action
R&D Progress
PG11100 Series
Product Description
Mechanism of Action
R&D Progress
PG11144
Product Description
Mechanism of Action
R&D Progress
PG11400 Series
Product Description
Mechanism of Action
R&D Progress
PG545
Product Description
Mechanism of Action
R&D Progress
Epigenetics series
Product Description
Mechanism of Action
R&D Progress
Heparanase Inhibitor Program
Product Description
Mechanism of Action
R&D Progress
LSD-1 Series
Product Description
Mechanism of Action
R&D Progress
Progen Pharmaceuticals Limited – Pipeline Analysis
Progen Pharmaceuticals Limited – Pipeline Products by Therapeutic Class
Progen Pharmaceuticals Limited Pipeline Products By Target
Progen Pharmaceuticals Limited – Pipeline Products by Route of Administration
Progen Pharmaceuticals Limited – Pipeline Products by Molecule Type
Progen Pharmaceuticals Limited - Dormant Projects
Progen Pharmaceuticals Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
PG562
Progen Pharmaceuticals Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 14, 2010: Progen Pharmaceuticals Ltd Announced Publication On PG11047
May 19, 2010: Progen Receives Muparfostat Patent In Europe
Sep 09, 2009: Progen Pharmaceuticals Announces Completion Of PG11047 Phase I Study
May 05, 2009: Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth - Lysine Specific Demethylase 1 (LSD1)
Aug 14, 2008: Progen Resumes Phase I Development Of Anti-Cancer Agent, PG11047, In Combination
May 15, 2008: Progen Resumes Phase I Development Of Anti-Cancer Agent, PG-11047
Feb 13, 2008: Progen Pharmaceuticals Presents Preliminary PI-88 Phase II Prostate Cancer Results At The American Society For Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
Dec 21, 2007: Progen Provides Update On Phase III Clinical Program For PI-88 In Liver Cancer
Nov 05, 2007: Progen Presents Additional Analysis Of Data From PI-88 Phase II Liver Cancer Study At American Association For The Study Of Liver Diseases
Nov 02, 2007: Progen Update On Phase III Clinical Program For PI-88 In Liver Cancer
Financial Deals Landscape
Progen Pharmaceuticals Limited, Deals Volume Summary, 2004 to YTD 2010
Progen Pharmaceuticals Limited, Deals Summary By Region, 2004 to YTD 2010
Progen Pharmaceuticals Limited, Deals Summary, 2004 to YTD 2010
Progen Pharmaceuticals Limited Detailed Deal Summary
Asset Purchase
KAI Pharmaceuticals Acquires Patents From Progen Pharmaceuticals
Merger
Avexa Terminates Merger Implementation Agreement With Progen Pharmaceuticals
Acquisition
Progen Pharmaceuticals Acquires Cellgate
Licensing Agreements
PharmaSynth Enters Into Licensing Agreement With Global TransBiotech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• International Military and Government Helicopter Survey